Global InformationBupropion information
 | |
 1 : 1 mixture (racemate) | |
| Clinical data | |
|---|---|
| Pronunciation | /bjuːˈproʊpiɒn/ bew-PROH-pee-on am-fa-BEW-teh-moan |
| Trade names | Wellbutrin, Zyban, others |
| Other names | Amfebutamone; 3-Chloro-N-tert-butyl-β-keto-α-methylphenethylamine; 3-Chloro-N-tert-butyl-β-ketoamphetamine; Bupropion hydrochloride[1] |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a695033 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | By mouth |
| Drug class | NDRI antidepressants |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 5-20% (estimate) |
| Protein binding | Bupropion: 84%[13] Hydroxybupropion: 77%[13] Threohydrobupropion: 42%[13] |
| Metabolism | Liver, intestines[15] |
| Metabolites | • Hydroxybupropion • Threohydrobupropion • Erythrohydrobupropion • Others |
| Elimination half-life | Bupropion: 11–21 h[14][15] Hydroxybupropion: 20 h[15] Threohydrobupropion: 37 h[15] Erythrohydrobupropion: 33 h[15] |
| Excretion | Urine: 87% (0.5% unchanged)[15] Feces: 10%[15] |
| Identifiers | |
IUPAC name
| |
| CAS Number |
|
| PubChem CID |
|
| IUPHAR/BPS |
|
| DrugBank |
|
| ChemSpider |
|
| UNII |
|
| KEGG |
|
| ChEBI |
|
| ChEMBL |
|
| CompTox Dashboard (EPA) |
|
| Chemical and physical data | |
| Formula | C13H18ClNO |
| Molar mass | 239.74 g·mol−1 |
| 3D model (JSmol) |
|
SMILES
| |
InChI
| |
| (verify) | |
Bupropion, formerly called amfebutamone,[16] and sold under the brand name Wellbutrin among others, is an atypical antidepressant primarily used to treat major depressive disorder and to support smoking cessation.[17][18] It is also popular as an add-on medication in the cases of "incomplete response" to the first-line selective serotonin reuptake inhibitor (SSRI) antidepressant.[18][19] Bupropion has several features that distinguish it from other antidepressants: it does not usually cause sexual dysfunction,[18] it is not associated with weight gain[18] and sleepiness,[20] and it is more effective than SSRIs at improving symptoms of hypersomnia and fatigue.[21] Bupropion, particularly the immediate release formulation, carries a higher risk of seizure than many other antidepressants, hence caution is recommended in patients with a history of seizure disorder.[22]
Common adverse effects of bupropion with the greatest difference from placebo are dry mouth, nausea, constipation, insomnia, anxiety, tremor, and excessive sweating.[23][failed verification] Raised blood pressure is notable.[24] Rare but serious side effects include seizures,[23] liver toxicity,[25] psychosis,[26] and risk of overdose.[27] Bupropion use during pregnancy may be associated with increased odds of congenital heart defects.[28]
Bupropion acts as a norepinephrine–dopamine reuptake inhibitor (NDRI) and a nicotinic receptor antagonist.[15] However, its effects on dopamine are weak and clinical significance is contentious.[29][30][31][32][33] Chemically, bupropion is an aminoketone that belongs to the class of substituted cathinones and more generally that of substituted amphetamines and substituted phenethylamines.[1][34]
Bupropion was invented by Nariman Mehta, who worked at Burroughs Wellcome, in 1969.[35] It was first approved for medical use in the United States in 1985.[36] Bupropion was originally called by the generic name amfebutamone, before being renamed in 2000.[16] In 2021, it was the eighteenth most commonly prescribed medication in the United States, with more than 29 million prescriptions.[37][38] It is on the World Health Organization's List of Essential Medicines.[39]
- ^ a b "Bupropion". PubChem. United States National Library of Medicine – National Center for Biotechnology Information. 28 July 2018. Archived from the original on 29 July 2018. Retrieved 29 July 2018.
- ^ "Bupropion Use During Pregnancy". Drugs.com. Archived from the original on 24 December 2018. Retrieved 24 December 2018.
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
- ^ "TGA eBS - Product and Consumer Medicine Information Licence". Archived from the original on 7 December 2016. Retrieved 9 January 2023.
- ^ Brazilian Health Regulatory Agency (Anvisa) (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 3 August 2023.
- ^ "Wellbutrin Product information". Health Canada. 25 April 2012. Archived from the original on 9 January 2023. Retrieved 9 January 2023.
- ^ "Zyban Product information". Health Canada. 25 April 2012. Archived from the original on 9 January 2023. Retrieved 9 January 2023.
- ^ "Zyban 150 mg prolonged release tablets - Summary of Product Characteristics (SmPC)". (emc). 21 April 2022. Archived from the original on 9 January 2023. Retrieved 9 January 2023.
- ^ Cite error: The named reference
Wellbutrin SR FDA labelwas invoked but never defined (see the help page). - ^ "Wellbutrin XL- bupropion hydrochloride tablet, extended release". DailyMed. 4 March 2022. Archived from the original on 9 January 2023. Retrieved 9 January 2023.
- ^ Cite error: The named reference
Aplenzin FDA labelwas invoked but never defined (see the help page). - ^ "Bupropion hydrochloride EPAR". European Medicines Agency. 17 September 2018. Archived from the original on 18 August 2022. Retrieved 7 March 2023.
- ^ a b c "Zyban 150 mg prolonged release film-coated tablets – Summary of Product Characteristics (SPC)". electronic Medicines Compendium. GlaxoSmithKline UK. 1 August 2013. Archived from the original on 20 July 2017. Retrieved 22 October 2013.
- ^ Cite error: The named reference
pmid27255113was invoked but never defined (see the help page). - ^ a b c d e f g h Cite error: The named reference
pmid31124380was invoked but never defined (see the help page). - ^ a b World Health Organization (2000). "International nonproprietary names for pharmaceutical substances (INN) : proposed international nonproprietary names : list 83". WHO Drug Information. 14 (2). hdl:10665/58135.
- ^ Sweetman S (2011). Martindale: The Complete Drug Reference (37th ed.). Pharmaceutical Press. p. 402. ISBN 9780853699828.
- ^ a b c d Cite error: The named reference
pmid27141292was invoked but never defined (see the help page). - ^ Cite error: The named reference
pmid27591914was invoked but never defined (see the help page). - ^ Cite error: The named reference
Dhillonwas invoked but never defined (see the help page). - ^ Cite error: The named reference
pmid16848671was invoked but never defined (see the help page). - ^ Steinert T, Fröscher W (July 2018). "Epileptic Seizures Under Antidepressive Drug Treatment: Systematic Review". Pharmacopsychiatry. 51 (4): 121–135. doi:10.1055/s-0043-117962. PMID 28850959. S2CID 22436728.
- ^ a b Cite error: The named reference
WellbutrinPIwas invoked but never defined (see the help page). - ^ Cite error: The named reference
pmid15705013was invoked but never defined (see the help page). - ^ Cite error: The named reference
pmid24362450was invoked but never defined (see the help page). - ^ Cite error: The named reference
Buproprion-induced psychosiswas invoked but never defined (see the help page). - ^ Cite error: The named reference
pmid28135844was invoked but never defined (see the help page). - ^ Cite error: The named reference
pmid33354752was invoked but never defined (see the help page). - ^ Cite error: The named reference
pmid33977870was invoked but never defined (see the help page). - ^ Cite error: The named reference
pmid24484978was invoked but never defined (see the help page). - ^ Cite error: The named reference
pmid28965364was invoked but never defined (see the help page). - ^ Cite error: The named reference
DeBattista2022was invoked but never defined (see the help page). - ^ Cite error: The named reference
pmid35068363was invoked but never defined (see the help page). - ^ Dye LR, Murphy C, Calello DP, Levine MD, Skolnik A (2017). Case Studies in Medical Toxicology: From the American College of Medical Toxicology. Springer. p. 85. ISBN 9783319564494. Archived from the original on 29 August 2021. Retrieved 5 June 2020.
- ^ Mehta NB (25 June 1974). "United States Patent 3,819,706: Meta-chloro substituted α-butylamino-propiophenones". USPTO. Archived from the original on 7 November 2017. Retrieved 2 June 2008.
- ^ Cite error: The named reference
approvalswas invoked but never defined (see the help page). - ^ "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
- ^ "Bupropion - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.
- ^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.